The spectrum of pulmonary vascular diseases includes pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and pulmonary veno-occlusive disease, each requiring distinct diagnostic and therapeutic pathways. Advancements in echocardiography, right heart catheterization, and cardiopulmonary exercise testing have improved disease characterization. Targeted therapies—such as endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogs—are central to modifying disease trajectory and enhancing exercise tolerance. Pulmonary Vascular Diseases also benefit from emerging research in vascular remodeling, endothelial dysfunction, and right ventricular adaptation. Surgical interventions, including pulmonary thromboendarterectomy and balloon pulmonary angioplasty, offer curative potential in select cases. Increasing awareness, earlier screening, and multidisciplinary coordination between pulmonology and cardiology are essential for optimizing care
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Non-canonical IRF3 functions in limiting pulmonary inflammation
Saurabh Chattopadhyay, University of Kentucky, United States
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : The representational challenge for designing and managing intelligent and ethical 5P medicine pulmonary, respiratory and lung health care systems
Habil Bernd Blobel, University of Regensburg, Germany
Title : From Chronic Obstructive Pulmonary Disease (COPD) to Non-Small Cell Lung Cancer (NSCLC): T helper cell epigenetic modifications and cancer risk
Koustav Sarkar, SRM Institute of Science and Technology, India
Title : Bacterial profile of community acquired pneumonia in a public health institute
Sayan Bhattacharyya, AIIH&PH, India